A Phase III, Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of 50 mg Oral Dosing With the Neurokinin-1 Receptor Antagonist GW679769 for the Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis.
Phase of Trial: Phase III
Latest Information Update: 04 Nov 2016
At a glance
- Drugs Casopitant (Primary) ; Ondansetron
- Indications Postoperative nausea and vomiting
- Focus Therapeutic Use
- 03 Dec 2007 Status changed from in progress to completed.
- 25 Jun 2007 New trial record.